Dextromethorphan for Psychiatric Indications
Yes, dextromethorphan has an FDA-approved psychiatric indication: it is approved in combination with bupropion (dextromethorphan/bupropion, AUVELITY) for the treatment of major depressive disorder (MDD) in adults. 1
FDA-Approved Psychiatric Use
The fixed-dose combination of dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg received FDA approval in August 2022 specifically for treating MDD in adults 1. This represents the first and only approved psychiatric indication for dextromethorphan.
Mechanism of Action in Depression
Dextromethorphan functions as:
- An uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist
- A sigma-1 receptor agonist
Bupropion serves dual purposes in this combination:
- Acts as a CYP2D6 inhibitor that increases dextromethorphan bioavailability
- Provides antidepressant effects through its aminoketone properties 1
This pharmacokinetic and pharmacodynamic synergy may account for the relatively rapid onset of antidepressant effects 2.
Clinical Evidence and Efficacy
The dextromethorphan/bupropion combination has demonstrated replicated, clinically significant antidepressant effects with relatively rapid onset in adults with MDD 2. A systematic review of preclinical and clinical studies confirms that this combination is well-tolerated and exhibits clinically significant antidepressant effects 2.
First-Line Treatment Considerations
Expert consensus recommendations (2026) support dextromethorphan-bupropion as a first-line treatment option for MDD, including in patients with co-occurring anxiety symptoms 3. The panel reached consensus on 27 recommendations with a mean agreement score of 3.8, indicating strong expert support 3.
Use in Treatment-Resistant Depression
Dextromethorphan-bupropion is specifically recommended for patients with:
- Inadequate response to prior MDD treatments
- Residual symptoms despite treatment
- Intolerable side effects from previous antidepressants 3
This addresses a critical gap, as conventional monoamine-based antidepressants leave a large percentage of adults with MDD insufficiently responding or experiencing intolerance 2.
Important Safety Considerations
Contraindications and Drug Interactions
Do not use dextromethorphan if the patient is currently taking a monoamine oxidase inhibitor (MAOI) or within 2 weeks of stopping an MAOI 4. This includes MAOIs used for depression, psychiatric conditions, emotional conditions, or Parkinson's disease.
When switching from or adding to current medications, carefully evaluate potential drug interactions consistent with the product label 3.
Switching from Ketamine/Esketamine
Exercise caution when switching from ketamine or esketamine to dextromethorphan-bupropion, with awareness of the short-to-intermediate elimination half-lives of these drugs 3.
Adverse Event Profile
Recent pharmacovigilance data (2022-2024) from the FDA Adverse Event Reporting System identified 3,580 adverse events associated with dextromethorphan-bupropion, primarily involving:
- Psychiatric disorders (21.17%)
- Nervous system disorders (20.92%)
- General disorders and administration site conditions (19.75%) 5
Notably, 65.3% of reported adverse events were not explicitly mentioned in the product labeling, suggesting previously unlabeled signals that warrant clinical vigilance 5.
Overdose Risk
A case report documented a suicide attempt involving approximately 30 tablets of dextromethorphan-bupropion 45-105 mg, requiring intubation and gastrointestinal decontamination 6. Clinicians must be particularly cautious when prescribing to populations at risk of overdose.
Investigational Psychiatric Uses
Bipolar Depression
Preliminary evidence suggests potential efficacy in adults with bipolar depression, though this remains investigational and requires further study 2.
Ongoing Research
A randomized controlled trial is evaluating dextromethorphan 30 mg once daily as add-on therapy to selective serotonin reuptake inhibitors (SSRIs) in MDD 7. This study aims to assess whether lower-dose dextromethorphan as adjunctive therapy can overcome therapeutic latency and improve outcomes.
Clinical Pitfalls to Avoid
Do not confuse over-the-counter dextromethorphan (used as a cough suppressant at 30 mg doses) with the prescription psychiatric formulation 4. The psychiatric indication requires the specific fixed-dose combination with bupropion.
Do not overlook MAOI interactions, which can be dangerous 4.
Monitor closely for psychiatric adverse events, as many are not listed in the original labeling 5.
Individualize treatment decisions prioritizing safety considerations noted in the Prescribing Information, particularly regarding drug interactions and patient-specific risk factors 3.
Bottom Line
Dextromethorphan has one established psychiatric indication: treatment of MDD in adults when combined with bupropion as the FDA-approved fixed-dose combination AUVELITY. This represents a mechanistically novel approach targeting glutamatergic signaling rather than traditional monoamine systems, offering an option for patients with inadequate response to conventional antidepressants. The combination demonstrates rapid onset of action and is supported by expert consensus as a first-line treatment option, though clinicians must remain vigilant for adverse events and drug interactions.